Silicon Valley biotech trading at .0065 and heading up, ARYC, updates:
Arrayit Silicon Valley store sales exceed $54 million all-time on 222,269 microarray products and services
Arrayit receives new financing lead that could generate 6,000 x $100K = $600MM in Arrayit microarray platform sales
Arrayit signs 3-year $24.4 million patented microarray technology sales and marketing agreement with a leading laboratory services provider.
Arrayit Corporation ?@arrayit
Arrayit quotes $16,000,000 microarray services contract to top US-based research laboratory http://arrayit.com/Services/services.html
Arrayit backorders soar to record $2.5MM on strong demand for microarray products & services
Arrayit Corporation http://www.arrayit.com/
Check out their Facebook page: Arrayit Corporation
Follow $ARYC on Twitter @Arrayit
Avant Diagnostics, Inc. provide the market’s first large panel biomarker monitoring test for ovarian cancer (OVC). OvaDx® is advanced microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Avant will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound.